Laureate To Make MAb for Neoprobe

Neoprobe Corp. and Laureate Pharma have entered into a Biopharmaceutical Development and Manufacturing Agreement under which Laureate will assist in the development and production of Neoprobe’s murine monoclonal antibody CC49. Also called RIGScan CR, CC49 is a tumor-specific targeting agent initially intended for use in treatment of colorectal cancer. Terms of the development and manufacturing agreement were not disclosed.

“We are delighted that Neoprobe has selected Laureate Pharma as their development and manufacturing partner,” said Robert J. Broeze, Ph.D., president and chief executive officer of Laureate Pharma. “We will work closely in partnership with the Neoprobe biotech team and assist them in driving their product from development into the clinic.”

“Laureate Pharma has an established track record in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials,” said David Bupp, president and chief executive officer of Neoprobe. “This agreement will allow us to leverage Laureate’s expertise and infrastructure while we seek to establish RIGScan CR as an improvement in the treatment for colorectal cancer.”